Webcast ImageWebcast
AMAG Pharmaceuticals, Inc. to Acquire Cord Blood Registry (Replay)
Jun.29.2015 at 8:00 a.m. ET
Webcast ImageWebcast
AMAG Pharmaceuticals, Inc. at Barclays High Yield Bond and Syndicated Loan Conference (Replay)
Jun.11.2015 at 1:25 p.m. MT

  AMAG 1Q 2015 Financial Results Presentation

AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.

AMAG’s lead product, a therapeutic iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD), has received regulatory approvals in the United States, European Union, Switzerland and Canada. To learn more about our products, click here.

Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company’s commercial footprint and focus on hematology and oncology centers and hospital infusion centers.

Contact Information
Linda Lennox
Vice President, Investor Relations & Corporate Communications
Phone: 617-498-2846